OncoMatch/Clinical Trials/NCT06990321
Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia
Is NCT06990321 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Intermediate-dose Cytarabine in Combination with Venetoclax for acute myeloid leukemia (aml).
Treatment: Intermediate-dose Cytarabine in Combination with Venetoclax — A Single-center, Single-arm, Prospective Clinical Study of Intermediate-dose Cytarabine in Combination with Venetoclax for Consolidation Therapy of Middle- and High-risk Acute Myeloid Leukemia in the Elderly
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: induction therapy
AML patients who achieve remission with morphologic assessment of bone marrow showing no leukemic involvement after induction therapy
Lab requirements
Kidney function
Serum creatinine < 2x ULN
Liver function
Total bilirubin ≤ 1.5x ULN; AST and ALT ≤ 2.5x ULN
Cardiac function
Ejection fraction within normal limits as determined by echocardiogram
Total bilirubin ≤ 1.5x ULN; AST and ALT ≤ 2.5x ULN; Serum creatinine < 2x ULN; Cardiac ejection fraction within normal limits as determined by echocardiogram
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06990321 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received induction therapy.
Is there an age limit?
Yes. Patients must be 75 years or younger and at least 60 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages